 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RD118 / IASO BIO
Enrollment open, CAR T-Cell Therapy: RD138CI002: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - Oct 11, 2023
P1, N=12, Recruiting, Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Not yet recruiting --> Recruiting
- || RD118 / IASO BIO
New P1 trial, CAR T-Cell Therapy: RD138CI002: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - Mar 8, 2023
P1, N=12, Not yet recruiting, Sponsor: Nanjing IASO Biotherapeutics Co.,Ltd
- | RD118 / IASO BIO
Enrollment open, Trial completion date, CAR T-Cell Therapy: CAR-GPRC5DCI001: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - May 23, 2022
P1, N=18, Recruiting, Sponsor: Chunrui Li
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Mar 2024
- | RD118 / IASO BIO
New P1 trial, CAR T-Cell Therapy: CAR-GPRC5DCI001: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - Feb 2, 2022
P1, N=18, Not yet recruiting, Sponsor: Huazhong University of Science and Technology